Retatrutide and Cognitive Function: Inside a New Preclinical Diabetic-Rat Study

What Did This New Retatrutide Study Investigate?

A preprint posted to bioRxiv in January 2026 and revised in April 2026 asks a narrower, more mechanistic question than the headline TRIUMPH obesity trials: does retatrutide, dosed in a rodent model of insulin-deficient diabetes, affect measures of learning and memory?[1] The paper, titled "Effects of Retatrutide on Learning and Memory in Streptozotocin-Induced Male Diabetic Rats," comes from a team at Kutahya Health Sciences University in Turkey and is also archived on SSRN.[2]

It is a preclinical, in vivo animal study — entirely separate from Eli Lilly's Phase 3 TRIUMPH programme in human obesity and type 2 diabetes, which is covered in our retatrutide research overview and Type 2 diabetes guide. Diabetes-associated cognitive impairment is a well-documented phenomenon in streptozotocin (STZ)-induced diabetic rodents, linked in the literature to hyperglycaemia-driven neuroinflammation, oxidative stress, and disrupted neurotrophic signalling in the hippocampus. Because retatrutide is a triple GLP-1/GIP/glucagon receptor agonist, and GLP-1 receptors are expressed on hippocampal and cortical neurons, the authors had an existing rationale — already explored for other incretin-class molecules such as liraglutide and semaglutide in prior rodent literature — for testing whether receptor agonism modifies diabetes-associated cognitive deficits in this model.

Velox Peptides supplies retatrutide as an HPLC-verified (≥99% purity) lyophilised reagent for in vitro research use only. View the product page →

How Was the Study Designed?

The study used adult male Sprague-Dawley rats allocated to four groups: an untreated control group, an STZ-induced diabetic group, an STZ-induced diabetic group treated with retatrutide, and a non-diabetic group treated with retatrutide alone. Diabetes was induced with a single dose of streptozotocin — a compound routinely used in rodent research to chemically destroy pancreatic beta cells and produce an insulin-deficient, type-1-like diabetic model. Retatrutide was administered subcutaneously at 0.015 mg/kg in a DMSO vehicle daily from day 1 to day 21.[1]

Cognitive outcomes were assessed with two standard rodent behavioural assays: the Morris Water Maze, which measures spatial learning and memory via escape-latency to a hidden platform, and the Passive Avoidance test, which measures short-term associative memory. At the tissue level, the researchers measured hippocampal cytokines (IL-1β and TNF-α), mRNA expression of BDNF, CREB, and AKT — three genes central to neurotrophic and synaptic-plasticity signalling — Tau protein levels, and cortical and hippocampal histopathology.[1]

What Did the Behavioural Testing Show?

In the Morris Water Maze, retatrutide-treated diabetic rats showed better-preserved overall performance relative to untreated diabetic rats, consistent with attenuation of the spatial-learning deficit associated with STZ-induced diabetes in this model. In the Passive Avoidance test, the effect was more limited and task-dependent: retatrutide was associated with a partial attenuation of short-term avoidance deficits rather than a complete normalisation across every memory measure tested.[1]

Notably, in the non-diabetic group treated with retatrutide alone, the peptide did not improve behavioural performance beyond control levels. The authors' framing is that retatrutide's behavioural effect in this model tracks with reversing diabetes-associated impairment specifically, rather than reflecting a general cognitive-enhancing property of the compound in healthy animals — an important distinction for anyone extrapolating from this dataset.

What Happened at the Molecular and Tissue Level?

At the tissue level, retatrutide-treated diabetic rats showed a significant reduction in hippocampal TNF-α, a pro-inflammatory cytokine strongly implicated in diabetes-associated neuroinflammation, alongside a non-significant trend toward lower IL-1β. Histopathological assessment found partial preservation of cortical and hippocampal cytoarchitecture in the treatment group compared with untreated diabetic animals.[1]

On the metabolic side, retatrutide reduced blood glucose in the diabetic group but did not achieve full euglycaemia, and it did not prevent diabetes-associated weight loss in this STZ model. This is an insulin-deficient, catabolic model of diabetes in which weight loss reflects disease severity rather than a treatment outcome, and it should not be conflated with the weight-related endpoints reported in Lilly's human obesity trials, which involve an entirely different disease model, species, and route of administration.

How Does This Fit Into the Wider Retatrutide Research Picture?

What Are the Limitations Researchers Should Note?

Several caveats matter for anyone citing this paper. First, as of publication it is a preprint posted to bioRxiv and SSRN; it has not completed formal peer review, and its conclusions should be treated as provisional pending publication in a peer-reviewed journal.[1][2] Second, the study's most recent revision (v2) restricted the cohort to male rats, so findings cannot be assumed to generalise across sex. Third, STZ-induced diabetes models severe, insulin-deficient (type-1-like) diabetes, which differs mechanistically from the type 2 diabetes and obesity populations studied in Lilly's human TRIUMPH and TRANSCEND trials. Fourth, the dosing regimen — 0.015 mg/kg/day for 21 days in a DMSO vehicle — is a rodent research protocol with no established translation to human dosing.

None of these findings constitute evidence of any cognitive effect of retatrutide in humans, and they do not describe any property of Velox Peptides' research-grade retatrutide product, which is supplied strictly for in vitro laboratory use and carries no therapeutic or health-benefit claims.

Velox Peptides Supply Information

Retatrutide is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions